The UMIN000011519 trial provided preliminary evidence that WT1-specific TCR-transduced autologous T cells are effective for refractory AML or high-risk MDS in HLA-A*24:02 patients (109, 130). The gene discussed is WT1; the disease is myelodysplastic syndrome.